Loading...
Market
What will be the competitive response to GSK's lupus drug acquisition by end of 2025?
2
Resolution / Starting Odds
Major acquisition by competitor • 25%
New drug development announced • 25%
Price reduction of existing drugs • 25%
No significant response • 25%
Press releases from competitors and industry analysis reports
Story
GSK Acquires Investigational Lupus Drug from Chimagen Biosciences for $850 Million
Oct 29, 2024, 12:13 PM
GSK has announced the acquisition of an investigational drug from Chinese biotech firm Chimagen Biosciences for up to $850 million. This move aims to enhance GSK's pipeline of potential treatments for lupus, addressing ongoing unmet needs in autoimmune diseases. The acquisition reflects GSK's strategy to expand its portfolio in the competitive biopharmaceutical market, particularly in the area of autoimmune disorders.
View original story
Similar markets
Pfizer • 25%
Johnson & Johnson • 25%
Roche • 25%
Other • 25%
Successful market introduction • 25%
Delayed market introduction • 25%
Project discontinued • 25%
Acquisition divested • 25%
Significant positive impact • 25%
Moderate positive impact • 25%
No significant impact • 25%
Negative impact • 25%
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Bristol-Myers Squibb • 25%
Novartis • 25%
Pfizer • 25%
Other • 25%
Biogen • 25%
Roche • 25%
Novartis • 25%
Other • 25%
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Moderna • 25%
Roche • 25%
Other • 25%